NephroGenex (NRX) and Mylan N.V. (NASDAQ:MYL) Financial Survey

NephroGenex (NASDAQ: NRX) and Mylan N.V. (NASDAQ:MYL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares NephroGenex and Mylan N.V.’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
NephroGenex	N/A	N/A	N/A	N/A	N/A
Mylan N.V.	$12.01 billion	1.37	$3.92 billion	$1.22	25.18

Mylan N.V. has higher revenue and earnings than NephroGenex.

Insider and Institutional Ownership

71.6% of Mylan N.V. shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NephroGenex and Mylan N.V.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NephroGenex	N/A	-211.97%	-105.90%
Mylan N.V.	5.51%	22.42%	7.54%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NephroGenex and Mylan N.V., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NephroGenex	0	0	1	0	3.00
Mylan N.V.	0	7	12	2	2.76

NephroGenex currently has a consensus price target of $17.50, indicating a potential upside of 12,391.08%. Mylan N.V. has a consensus price target of $48.05, indicating a potential upside of 56.42%. Given NephroGenex’s stronger consensus rating and higher probable upside, equities analysts plainly believe NephroGenex is more favorable than Mylan N.V..

Summary

Mylan N.V. beats NephroGenex on 8 of the 10 factors compared between the two stocks.

NephroGenex Company Profile

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.